[Effects of laser therapy in patients with functional class II-IV effort angina (using instrumental techniques of the study)]. / Effektivnost' lazernoi terapii u bol'nykh so stenokardiei napriazheniia II-IV funktsional'nogo klassa (s ispol'zovaniem instrumental'nykh metodov issledovaniia).

Infrared laser therapy using an arsenide-gallium laser was used in 54 patients aged 30-75 years who suffered from coronary heart disease. A positive clinical effect was achieved in 47 (87%) of 54 patients, as evidenced by the reduced number of nitroglycerin tablets used and improved bicycle ergometric, echo- and electrocardiographic parameters in the patients.

[Effects of nirmin on central hemodynamics in patients with heart failure in the acute period of myocardial infarct]. / Vliianie nirmina na tsentral'nuiu gemodinamiku u bol'nykh s serdechnoi nedostatochnost'iu v ostrom periode infarkta miokarda.

Nirmin, a novel dosage form of nitroglycerin, was used to treat heart failure in 47 patients on days 1-3 after acute myocardial infarction. The drug was intravenously injected at 12-400 micrograms/min for 3-24 hours. Central hemodynamic changes were evaluated from equilibrium radionuclide ventriculographic data and pulmonary diastolic and central venous pressures. Nirmin improved the clinical status in 89.3% of the patients. Hemodynamic effects of the agent were manifested by reduced myocardial preload and its improved contractility, followed by elevated left ventricular ejection fraction and decreased hypokinesia of the myocardial affected areas.

[Use of beta-methyldigoxin preparations medilazine and bemecor in patients with congestive heart failure]. / Primenenie preparatov beta-metildigoksina medilazina i bemekora u bo'lnykh s zastoinoi serdechnoi nedostatochnos'tiu.

The two agents beta-methyldigoxin (medixin), a Soviet medilazide, and bemecor (digicor), a foreign analogue (LEK, Yugoslavia) were comparatively evaluated. An equal high (85%) clinical efficacy of the drugs was found in 81 patients with varying stages of heart failure. A positive therapeutic effect was accompanied by lower heart rate, higher diuresis and natri-and kaliuresis, decreased systolic and diastolic pressures in the pulmonary artery. The incidence of adverse reactions and the causes of their occurrence are analyzed.

[Use of prolecofen in the treatment of arrhythmia in patients with ischemic heart disease]. / Primenenie prolekofena dlia lecheniia aritmii u bol'nykh ishemicheskoi bolezn'iu serdtsa.

A new antiarrhythmic drug, prolecofen (class Ic), was used in 74 patients with various forms of coronary heart disease, involving heart rhythm disorders. The drug's clinical efficiency and effects on platelet activity, lipid peroxidation, blood prostacyclin, thromboxane, cAMP and cGMP were assessed. Prolecofen is shown to be an effective agent for the treatment of ventricular and supraventricular arrhythmias in coronary patients. It contributes to the inhibition of platelet activity, a drop of cAMP and cGMP levels and a rise of the cAMP/cGMP ratio.

[Blood rheological effects in ischemic heart disease treated with antianginal and thrombolytic agents]. / Gemoreologisheskie éffekty u bol'nykh ishemicheskoi bolezn'iu serdtsa pri lechenii antianginal'nymi i tromboliticheskimi sredstvami.

In 161 patients with different forms of ischaemic heart disease the authors studied changes of the blood viscosity, erythrocyte aggregation and of thrombocytes during treatment with modern antianginal and the thrombolytic agents. Treatment with nitroglycerin in tablets and Sustac revealed no statistically significant differences in the changes of the haemorheological parameters. The mainly thrombocyte disaggregational effect was shown by micristin (aspirin/propranolol in the daily dose of over 120 mg) and verapamil (the daily dose over 160 mg). The use of dipyridamol, trental and nonachlazin was accompanied both by the decrease of functional activity of thrombocytes and by the decrease of the blood viscosity as a result of improvement of the functional properties of erythrocytes. Sodium nitroprusside depressed shortly the aggregation of platelets and decreased the blood viscosity at the expense of the decrease of the haematocrit. The use of streptokinase (avelisine) in patients with acute myocardial infarction was accompanied by defibrinisation of the blood, by marked decrease of the aggregation facility of formed elements of the blood and its viscosity. The results suggest that the haemorheological mechanisms participate in the antianginal effect of the drugs studied.

[Thrombocyte and erythrocyte aggregation in congestive circulatory insufficiency]. / Agregatsiia trombotsitiov i éritrotsitov pri zastoinoi nedostatochnosti krovoobrashcheniia

In 58 patients with Stage II-III congestive circulatory insufficiency photometric techniques permitted to reveal an increased aggregation of platelets and erythrocytes. The increased erythrocytes aggregation in congestive circulatory insufficiency correlated with an increased sodium content in the erythrocytes (r = +0,82) and total body content of water (r = +0,62). The mechanisms of increased platelets and erythrocytes aggregation are discussed, as well as their role in microcirculation disorders observed in circulatory insufficiency.